Xeris Biopharma: Strong 2025 Outperformance and Underappreciated Multiyear Growth Drive Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Brandon Folkes has reiterated a Buy rating on Xeris Pharmaceuticals, setting a price target of $10.00. This rating is based on Xeris's stronger-than-expected 2025 performance, which exceeded management guidance and market expectations. The company's solid commercial execution and growing revenues from key products like Recorlev, Gvoke, and Keveyis support this outlook. Folkes believes the current valuation does not fully reflect Xeris's multiyear growth potential, suggesting substantial upside as the market recognizes the company's long-term projections.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments